NCT04359654View on ClinicalTrials.gov

Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019)

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

August 12, 2021

Study Completion Date

November 5, 2021

Conditions
COVID-19 (Coronavirus Disease 2019)Hypoxia
Interventions
DRUG

Dornase Alfa Inhalation Solution [Pulmozyme]

Nebulised Dornase alfa 2.5mg bd for 7 days

Trial Locations (1)

NW1 2BU

University College London Hospital, London

All Listed Sponsors
lead

University College, London

OTHER

NCT04359654 - Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019) | Biotech Hunter | Biotech Hunter